Sa1061 Similar GI Side Effects With Once-Daily Versus Twice-Daily Dosing Ribavirin in HCV-Positive Patients on Triple Therapy

BACKGROUND: Triple therapy for one week with omeprazole, clarithromycin and metronidazole (OCM) is accepted worldwide as a first line therapy forHelicobacter pylorieradication. It is unclear whether omeprazole needs to be given once or twice daily.OBJECTIVES: To assess the efficacy and safety of these regimens in a single-centre, Canadian practice.METHODS: Histologically provenH pylori-positive patients were treated for seven days with clarithromycin 250 mg bid and metronidazole 500 mg bid, and randomly allocated to omeprazole 20 mg either once or twice daily in this open, cohort study. Endoscopy with histology (two antrum and two body biopsies, Giemsa stain) was done four weeks or longer after the pills were completed to assessH pylorieradication.RESULTS: Whether omeprazole was given once or twice daily, eradication was high and the same in both arms. All-patients-treated eradication was 85% (39 of 46 in the omeprazole once daily group and 41 of 48 in the omeprazole twice daily group) and intent-to-treat eradication was 80% (39 of 49 in the omeprazole once daily group and 41 of 51 in the omeprazole twice daily group). Side effects were frequently seen, suffered by 65% to 69% of patients treated. However, these were mild and compliance was high, with 94% of patients taking all of their pills. Mild side effects included loose stools, taste disturbance, nausea, headache and upper or lower gastrointestinal gas. Only one patient (1%) from the omeprazole once daily arm stopped taking metronidazole due to excessive perspiring.CONCLUSIONS: In this community practice, OCM triple therapy was effective whether omeprazole was given once or twice daily. For those with financial constraint, omeprazole 20 mg once daily can be considered. The regimens were well tolerated without serious adverse events.

Download Full-text

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

npj Primary Care Respiratory Medicine ◽

10.1038/s41533-021-00241-z ◽

2021 ◽

Vol 31 (1) ◽

Author(s):

Sandeep Bansal ◽

Martin Anderson ◽

Antonio Anzueto ◽

Nicola Brown ◽

Chris Compton ◽

...

Keyword(s):

Health Status ◽

Triple Therapy ◽

Treatment Guidelines ◽

Forced Expiratory Volume ◽

Chronic Obstructive ◽

Fluticasone Furoate ◽

Double Blind ◽

Once Daily ◽

Copd Patients ◽

Severe Copd

AbstractChronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD patients, with a similar safety profile.

Download Full-text

Profile study of side effects during triple therapy (omeprazole, amoxycillin, tinidazole) in 52 patients infected by helicobacter pylori

Gastrointestinal Endoscopy ◽

10.1016/s0016-5107(96)80238-0 ◽

1996 ◽

Vol 43 (4) ◽

pp. 350

Author(s):

G. Delpre ◽

E. Livni ◽

Y. Niv

Keyword(s):

Helicobacter Pylori ◽

Side Effects ◽

Triple Therapy ◽

Profile Study

Download Full-text

Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study

British Journal of Clinical Pharmacology ◽

10.1111/bcp.13796 ◽

2018 ◽

Vol 85 (1) ◽

pp. 277-280

Author(s):

Minh P. Lê ◽

Marie‐Laure Chaix ◽

François Raffi ◽

Sylvie Chevret ◽

Sébastien Gallien ◽

...

Keyword(s):

Triple Therapy ◽

Once Daily ◽

Therapy Efficacy

Download Full-text

Once-Daily Treatment for Mixed Anxiety/Depressive States: A Comparison of Slow Release Amitriptyline and Fluphenazine with Nortriptyline

Journal of International Medical Research ◽

10.1177/030006057700500206 ◽

1977 ◽

Vol 5 (2) ◽

pp. 109-113 ◽

Cited By ~ 3

Author(s):

R V Magnus ◽

A A Schiff

Keyword(s):

Side Effects ◽

Sustained Release ◽

Slow Release ◽

Anxiolytic Effect ◽

Daily Treatment ◽

Dry Mouth ◽

Double Blind ◽

Once Daily ◽

Therapeutic Advantage ◽

Depressive States

Patients suffering from mixed anxiety/depressive states referred to a psychiatric out-patient clinic completed a four week course of either a once-daily tablet of 30 mg nortriptyline with 1· 5 mg fluphenazine, or a sustained release capsule of 50 mg amitriptyline once daily, on a double-blind basis. Depression improved satisfactorily on either treatment, but there was a greater reduction of anxiety on fluphenazine/nortriptyline. Drowsiness, however, occurred more frequently among the patients on amitriptyline, suggesting the sedative properties of this drug did not substitute adequately for a specific anxiolytic effect. Dry mouth was also noticeably more frequent with amitriptyline. As might be expected on pharmacokinetic and physiological grounds, the results suggest that the sustained release characteristics of the amitriptyline preparation lead to a maximization of side-effects during the day without conferring any therapeutic advantage.

Download Full-text

Topical Isotretinoin in Acne Vulgaris

TAJ Journal of Teachers Association ◽

10.3329/taj.v29i2.39099 ◽

2018 ◽

Vol 29 (2) ◽

pp. 1-5

Author(s):

M Moksedur Rahman ◽

M Abdullah ◽

M Moazzem Hossain ◽

MA Siddique ◽

M Nessa ◽

...

Keyword(s):

Side Effects ◽

Adverse Effects ◽

Prospective Study ◽

Acne Vulgaris ◽

Topical Therapy ◽

Outpatient Department ◽

College Hospital ◽

Once Daily ◽

Medical College ◽

Cutaneous Reactions

This study was carried out to evaluate the efficacy, safety and adverse effects of topical isotretinoin 0.05% gel in the treatment of acne vulgaris. This prospective study was undertaken in Skin & VD outpatient department of Rajshahi Medical College Hospital, Rajshahi. One hundred patients with mild tomoderate acne vulgaris were enrolled and were instructed to apply isotretinoin 0.05% gel once daily at night for 12 weeks. Patients were followed up at 2,4,8 and 12 weeks for efficacy and tolerability. Efficacy was measured by counting facial inflammatory and noninflammatory lesions and by grading acne severity. Cutaneous tolerance was assessed by determining erythema, scaling and burning with pruritus.Response was excellent in 80%of cases.None of the cutaneous reactions was severe, all were mild and well tolerated.Nobody had to discontinue the therapy for side effects. This study confirms that isotretinoin 0.05% gel is safe and effective topical therapy for mild to moderate acnevulgaris.TAJ 2016; 29(2): 1-5

Download Full-text

The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease

Terapevticheskii arkhiv ◽

10.26442/00403660.2019.08.000382 ◽

2019 ◽

Vol 91 (8) ◽

pp. 28-33 ◽

Cited By ~ 1

Author(s):

A M Veliev ◽

I V Maev ◽

D N Andreev ◽

D T Dicheva ◽

A V Zaborovskii ◽

...

Keyword(s):

Duodenal Ulcer ◽

Helicobacter Pylori ◽

Side Effects ◽

Triple Therapy ◽

Eradication Therapy ◽

Test System ◽

Efficacy And Safety ◽

Concomitant Therapy ◽

Quadruple Therapy ◽

H Pylori

Aim. Evaluation of the efficacy and safety of quadrupletherapy without bismuth (concomitant therapy) in patients with Helicobacter pylori - associated gastric ulcer and duodenal ulcer in the framework of a comparative research in the population of patients in Russia. Materials and methods. A prospective randomized trial was conducted, which included 210 patients with H. pylori - associated gastric/duodenal ulcer without complications. During the process of randomization, the patients were divided into three equal groups (n=70) depending on the prescribed 10-day scheme of eradication therapy (ET): the first group received the classic triple scheme (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day and Clarithromycin 500 mg 2 times a day); the second group received quadruple therapy with bismuth drugs (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day); the third group received quadruple therapy without bismuth - concomitant therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day and Metronidazole 500 mg 2 times a day). Diagnostics of H. pylori infection during screening and control of eradication was carried out via the fast urease biopsy sample test and urea breath test system. Control of the effectiveness of ET of the microorganism was carried out not earlier than 4 weeks after the end of the treatment. During the course of therapy, the frequency of development of side effects was assessed using a special questionnaire. Results and discussion. The effectiveness of triple therapy was 72.8% (ITT; 95% CI of 62.17-83.54) and 78,4% (PP; 95% CI 68.19-88.72); quadruple therapy with the preparation of bismuth - 80.0% (ITT; 95% CI 70.39-89.6) and 84,8% (PP; 95% CI, 75.96-93.73); quadruple therapy without bismuth - concomitant therapy - 84.2% (ITT; 95% CI 75.54-93.02) and 92.1% (PP; 95% CI 85.43-98.94). Quadruple therapy without bismuth was reliably more effective than the classical triple therapy in the PP selection (p=0.044883). Statistical analysis showed a tendency to poorer effectiveness of ET in patients who had previously used antibiotic therapy (OR 0.4317; 95% CI 0.1776-1.049), and in individuals with a rapid metabolism genotype - CYP2C19*1/*1 (OR 0.12; 95% CI 0.005848-2.4624). The frequency of development of side effects during the use of triple therapy was 18.5% (95% CI of 9.23-27.91), when using quadruple therapy with bismuth - 20.0% (95% CI 10.39-29.6), and with the use of quadruple therapy without bismuth - concomitant therapy - 24.2% (95% CI 13.98-34.58). Conclusion. This prospective randomized study demonstrated the high efficiency of quadruple therapy without bismuth (concomitant therapy) in the framework of eradication of H. pylori infection in Russia.

Download Full-text

Oral Sildenafil in the Treatment of Erectile Dysfunction

50 Studies Every Urologist Should Know ◽

10.1093/med/9780190655341.003.0043 ◽

2021 ◽

pp. 245-250

Author(s):

Joshua Bodie

Keyword(s):

Erectile Dysfunction ◽

Side Effects ◽

Sexual Activity ◽

Once Daily ◽

Higher Doses ◽

Different Doses ◽

Visual Disturbances ◽

Better Than

This chapter summarizes the results of a landmark trial comparing different doses of oral sildenafil versus placebo to treat erectile dysfunction. Patients received either an identical placebo or 25- mg, 50-mg, or 100-mg tablets of sildenafil to be taken approximately one hour before planned sexual activity (but not more than once daily) for 24 weeks. Higher doses of sildenafil resulted in higher mean score for frequency of penetration and maintenance of erection, which were also consistently better than placebo. The most common side effects were headaches, flushing, dyspepsia, rhinitis, and visual disturbances. This study established sildenafil as an effective, reasonably well-tolerated treatment for men with erectile dysfunction of varying etiologies.

Download Full-text

Comparison of finasteride versus flutamide in the treatment of hirsutism

Acta Endocrinologica ◽

10.1530/eje.0.1410361 ◽

1999 ◽

pp. 361-367 ◽

Cited By ~ 54

Author(s):

L Falsetti ◽

A Gambera ◽

L Legrenzi ◽

C Iacobello ◽

G Bugari

Keyword(s):

Side Effects ◽

Polycystic Ovary ◽

Randomized Study ◽

Dry Skin ◽

Ovary Syndrome ◽

Once Daily ◽

Idiopathic Hirsutism ◽

Androstanediol Glucuronide ◽

To Receive ◽

Hair Diameter

OBJECTIVE: To compare the effectiveness of finasteride and flutamide in the treatment of hirsutism in patients with polycystic ovary syndrome (PCOS) and with idiopathic hirsutism. DESIGN: Randomized study. PATIENTS: One hundred and ten hirsute patients were selected: 64 women with PCOS and 46 with idiopathic hirsutism. METHODS: Patients were assigned randomly to receive 5mg finasteride once daily or 250mg of flutamide twice daily, for 12 consecutive months. Hirsutism was evaluated at 12 months of therapy, with the Ferriman-Gallwey score and with measurement of the terminal hair diameters (microm) taken from four different body areas. Blood samples were taken for assessment of endocrine and hematochemical parameters. Side effects were monitored during the treatment. RESULTS: Both finasteride and flutamide induced a significant decrease in the hirsutism scores and hair diameters at the end of 12 months. Finasteride reduced the Ferriman-Gallwey score by 31.4% in the PCOS cases and by 34.2% in the idiopathic hirsutism cases, and hair diameter by 27.0-34.1% in PCOS and by 29.6-37.9% in idiopathic hirsutism. Flutamide reduced the Ferriman-Gallwey score by 56.7% in PCOS and by 50.9% in idiopathic hirsutism, and hair diameter by 50. 3-60.0% in PCOS and by 47.7-56.5% in idiopathic hirsutism. Flutamide did not induce hormone variations, while finasteride increased testosterone levels by 40% in PCOS and by 60% in idiopathic hirsutism and decreased 3alpha-androstanediol glucuronide (3alpha-diolG) by 66.7% in PCOS and by 69.5% in idiopathic hirsutism. No important side effects or changes in the hematochemical parameters were observed with finasteride, while two patients (3.6%) in the flutamide group expressed abnormal transaminase levels after 6 months of treatment. Dry skin also appeared significantly more with flutamide (67.3%) than with finasteride (23.6%). CONCLUSIONS: Both drugs are effective in the treatment of hirsutism but flutamide is more effective than finasteride.

Download Full-text